Strativa Pharmaceuticals Acquires Commercialization Rights to Thin Film Formulation of Ondansetron From ...(with MonoSol Rx and expand our pipeline ...),Health

Date:6/17/2008

with MonoSol Rx and expand our pipeline of supportive care products." Mr. MacPhee continued, "With two unique, yet complementary delivery systems of ondansetron in our portfolio, Zensana(TM) oral spray and the oral thin film, we are able to offer patients a better opportunity to find a product that meets their individual needs."

A. Mark Schobel, president and CEO of MonoSol Rx, stated, "Strativa is uniquely positioned to market and sell our ondansetron thin film product and we are very excited about the collaboration," Mr. Schobel continued, "Following approval, ondansetron would be one of the first prescription drugs to come to market utilizing thin film drug delivery technology."

About Strativa

Strativa Pharmaceuticals is the proprietary products division of Par Pharmaceutical, Inc. Supported by Par's financial and organizational capabilities including substantial cash resources, Strativa Pharmaceuticals is committed to developing and marketing novel prescription drugs. Its initial focus is on supportive care therapeutics in HIV and oncology. Drawing on the specialty products expertise of its staff, Strativa possesses the resources to prepare products for introduction and to help ensure their success after launch. For additional information, please visit http://www.strativapharma.com.

About Par Pharmaceutical

Par Pharmaceutical, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit http://www.parpharm.com.

About MonoSol Rx

MonoSol Rx is a drug delivery company specializing in proprietary, dissolving thin film pharmaceutical products. The Company's thin film technology, which is similar in size, shape and thickness to a postage stamp, dissolves rapidly and utilizes a novel process and proprieta
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical
2. Verus Pharmaceuticals Announces Divestiture of Pediatric GI Development Program to Meritage Pharma
3. Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals
4. Alseres Pharmaceuticals, Inc.s Chairman, Peter Savas, Reviews Companys Progress in its Annual Letter to Stockholders
5. Jazz Pharmaceuticals Announces Development Timeline Updates
6. GlaxoSmithKline Acquires Sirtris Pharmaceuticals, Inc., a World Leader in Sirtuin Research and Development
7. Renhuang Pharmaceuticals, Inc. Holds Trade Show for Tianma Pills; Signs Letters of Intent
8. Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status
9. MAP Pharmaceuticals to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
11. Antipodean Pharmaceuticals Announces FDA Acceptance of IND for MitoQ(R)